S. Vincent Rajkumar

Professor of Medicine

Mayo Clinic Minnesota

United States

Research Interests

Explore related searches

Professors in United States Professors in Medical Imaging Medical Imaging professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. S. Vincent Rajkumar is a Professor of Medicine at Mayo Clinic in Minnesota, USA. His research primarily focuses on multiple myeloma and related clonal plasma cell disorders, as reflected in his recent publications. Key areas of interest include risk stratification, individualized treatment approaches, and advancements in immunotherapy for multiple myeloma. He actively contributes to advancing clinical understanding and management strategies in the field.

Articles (22)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (3)

Fieke Hoff

University of Texas Southwestern Medical Center

UNITED STATES

View details

Pedro Horna

Associate Professor

Mayo Clinic Rochester

UNITED STATES

View details

Sagar Lonial

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

S. Vincent Rajkumar

Research Interests

Explore related searches

Contact this professor

About

Articles (22)

Peripheral Blood Flow Cytometry-based Definition of Plasma Cell Leukemia

Defining IgM Multiple Myeloma

Solitary but not simple─a call for precision risk stratification and individualized treatment in solitary plasmacytoma

Current risk stratification and staging of multiple myeloma and related clonal plasma cell disorders

Time for a paradigm shift in immunotherapy-based BCMA/CD3 bispecific drug development in multiple myeloma

Multiple myeloma: 2024 update on diagnosis, risk‐stratification, and management

Three‐dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma

Performance of newer myeloma staging systems in a contemporary, large patient cohort

Phase III randomized trial of Thal+ZLD versus ZLD in patients with asymptomatic multiple myeloma – updated results after 18-year follow-up

Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis

Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database

Multiple myeloma with acute light chain cast nephropathy

Artificial intelligence-enabled screening strategy for drug repurposing in monoclonal gammopathy of undetermined significance

Once-weekly bortezomib as the standard of care in multiple myeloma: results from an international survey of physicians

Second- and third-line treatment strategies in multiple myeloma: a referral-center experience

Monoclonal Gammopathy of Undetermined Significance

Smoldering multiple myeloma current treatment algorithms

Comparison of two free light chain assays: performance of the involved free light chain ratio and implications for diagnosis of multiple myeloma

Cardiovascular Associations With Monoclonal Gammopathy of Undetermined Significance

Multiple myeloma: 2022 update on diagnosis, risk stratification, and management

Distribution of clonal hematopoiesis of indeterminate potential (CHIP) is not associated with race in patients with plasma cell neoplasms

Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota

Collaborators (3)

Fieke Hoff

Pedro Horna

Sagar Lonial

Make your next move.